Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Clinical trial NCT06456138 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06456138
Sponsor: Shanghai Chest Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

KRAS Mutation-Related Tumors Advanced Lung Cancer Refractory Tumor

Start date: 2024-07-01
Primary completion: 2026-06-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.